Author: Arnold, Samuel L.M.; Buckner, Frederick
Title: Hydroxychloroquine for Treatment of SARSâ€CoVâ€2 Infection? Improving Our Confidence in a Modelâ€Based Approach to Dose Selection Cord-id: 248de4cj Document date: 2020_5_9
ID: 248de4cj
Snippet: In less than six months, COVID-19 has spread from a marketplace in Wuhan, China to over 150 countries and territories of the world. Therapeutics are desperately needed to reduce the morbidity and mortality of this pandemic disease. It has been reported that hydroxychloroquine (HCQ) is active against SARS-CoV-2 in vitro, and this finding was quickly supported by an open label non-randomized clinical trial that provided the first published clinical evidence HCQ may be a treatment option.
Document: In less than six months, COVID-19 has spread from a marketplace in Wuhan, China to over 150 countries and territories of the world. Therapeutics are desperately needed to reduce the morbidity and mortality of this pandemic disease. It has been reported that hydroxychloroquine (HCQ) is active against SARS-CoV-2 in vitro, and this finding was quickly supported by an open label non-randomized clinical trial that provided the first published clinical evidence HCQ may be a treatment option.
Search related documents:
Co phrase search for related documents- active therapeutic and lung epithelium: 1
- additional concern and low concentration: 1
- low concentration and lung concentration: 1
- low respiratory and lung level: 1
- low respiratory and lung model: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date